Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E1WY
|
|||
| Former ID |
DNC009026
|
|||
| Drug Name |
EFIPLADIB
|
|||
| Synonyms |
Efipladib; 381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Terminated | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C40H35Cl3N2O4S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCCC6=CC=C(C=C6)C(=O)O
|
|||
| InChI |
1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)
|
|||
| InChIKey |
HIZOPJQOPKRKFM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 381683-94-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem. 2008 Jun 26;51(12):3388-413. | |||
| REF 2 | Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.